Coronary Artery Disease Clinical Trial
— PIONEER-IVOfficial title:
Non-inferiority of Angiography-derived Physiology Guidance Versus Usual Care in an All-comers PCI Population Treated With Unrestricted Use of the Healing-Targeted Supreme (HT Supreme) Drug-eluting Stent and P2Y12 Inhibitor Monotherapy After 1-month of Dual-antiplatelet Therapy
PIONEER-IV is a prospective, single-blind (patient), randomized, 1:1, controlled, multi-center study comparing clinical outcomes between angiography-derived physiology guidance to LRDP and usual care in an all-comers patient population (including patients with high bleeding risk, HBR) undergoing PCI with unrestrictive use of the HT Supreme sirolimus-eluting stent. Patients will be randomized to either angio-based physiology guidance angio-FFR (Quantitative Flow Ratio and coronary angiography-derived FFR, caFFR) or local routine diagnostic procedure (LRDP) and usual care. Patients will be treated with 1-year P2Y12 inhibitor monotherapy after 1-month of dual-antiplatelet therapy in approximately 2540 (2*1270) patients. All patients (both cohorts) must receive dual anti-platelet therapy, being aspirin (ASA) and ticagrelor for 1 month, followed by 11 months of ticagrelor only (i.e. monotherapy). At 1 year, ticagrelor monotherapy is replaced by aspirin monotherapy or left to the discretion of the operator.
Status | Recruiting |
Enrollment | 2540 |
Est. completion date | January 2029 |
Est. primary completion date | January 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient has chronic stable angina, acute coronary syndromes or silent ischemia; - Presence of one or more coronary artery stenoses of =50% (by visual assessment) in a native coronary artery (with or without prior stent/other device treatment) or in a saphenous venous or arterial bypass conduit suitable for coronary stent implantation; - The vessel should have a reference vessel diameter of at least 2.25 mm by visual assessment (no limitation on the number of treated lesions, vessels, or lesion length); - Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Ethical Committee and is willing to comply with all protocol-required (follow-up) evaluations. Exclusion Criteria: 1. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential according to local practice); 2. Known intolerance to cobalt chromium, and medications such as sirolimus, aspirin, heparin, bivalirudin or P2Y12 inhibitors; 3. Planned major elective surgery requiring discontinuation of (dual)anti platelet therapy (DAPT) within 12 months of procedure; 4. Concurrent medical condition with a life expectancy of less than 3 years; 5. Currently participating in another trial and not yet at its primary endpoint; 6. Active pathological bleeding; 7. History of intracranial haemorrhage. |
Country | Name | City | State |
---|---|---|---|
Belgium | ASZ Aalst | Aalst | |
Belgium | OLVZ Aalst | Aalst | |
Belgium | Imelda Ziekenhuis | Bonheiden | |
Belgium | CHU Charleroi | Charleroi | |
Belgium | Jessa Hospital Hasselt | Hasselt | |
Ireland | University Hospital Galway | Galway | |
Netherlands | OLVG Amsterdam | Amsterdam | |
Netherlands | Medisch Spectrum Twente, Thoraxcentrum, Endchede | Enschede | |
Netherlands | UMC Groningen | Groningen | |
Netherlands | Den Haag Ziekenhuis | Hague | |
Netherlands | Medisch Centrum Leeuwarden | Leeuwarden | |
Netherlands | Maasstad Ziekenhuis | Rotterdam | |
Spain | Hospital Clínico de Barcelona | Barcelona | |
Spain | Lucas Augusti Hospital | Lugo | |
Spain | Hospital Clínico Universitario of Valladolid | Valladolid | |
Spain | Hospital Álvaro Cunqueiro Vigo | Vigo | |
United Kingdom | Barts Health NHS Trust, London | London | |
United Kingdom | Freeman Hospital | Newcastle | |
United Kingdom | University Hospitals Southampton | Southampton |
Lead Sponsor | Collaborator |
---|---|
National University of Ireland, Galway, Ireland |
Belgium, Ireland, Netherlands, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient-oriented Composite Endpoint (PoCE) | PoCE is a composite clinical endpoint of: all-cause death; any stroke, Modified Rankin scale, (MRS =1); any myocardial infarction; any clinically and physiologically driven revascularization. |
12 months | |
Secondary | Vessel-oriented composite endpoints (VoCE) | VoCE is a composite clinical endpoint of: Vessel-related cardiovascular Death Target-vessel related MI Clinically and physiologically-oriented Target vessel revascularization |
12, 24 and 36 months | |
Secondary | Device-oriented composite endpoint (DoCE) | DoCE is a composite endpoint of: Cardiovascular Death Target-vessel related MI Clinically and physiologically-oriented Target lesion revascularization |
12, 24 and 36 months | |
Secondary | Myocardial Infarction (MI) | Peri-procedure Myocardial Infarction according to 4th universal definition | 48 hours post-procedure | |
Secondary | Device Success Rate | according to the statement from European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology (ESC) | index procedure | |
Secondary | Stent Thrombosis | Definite, Probable, Definite or Probable | Procedure, 12, 24 and 36 months | |
Secondary | Target Vessel Failure (TVF) | TVF is a composite of: Cardiovascular Death Target-vessel related MI Clinically and physiologically-oriented Target vessel revascularization |
12, 24 and 36 months | |
Secondary | Bleeding | Bleeding according to Bleeding Academic Research Consortium (BARC) (BARC 2, 3 and 5) classification | 12, 24 and 36 months follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06030596 -
SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
|
||
Completed |
NCT04080700 -
Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
|
||
Recruiting |
NCT03810599 -
Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study
|
N/A | |
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT05308719 -
Nasal Oxygen Therapy After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04242134 -
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
|
N/A | |
Completed |
NCT04556994 -
Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients.
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Recruiting |
NCT05023629 -
STunning After Balloon Occlusion
|
N/A | |
Completed |
NCT04941560 -
Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
|
||
Completed |
NCT04006288 -
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01860274 -
Meshed Vein Graft Patency Trial - VEST
|
N/A | |
Recruiting |
NCT06174090 -
The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients
|
N/A | |
Completed |
NCT03968809 -
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
|
||
Terminated |
NCT03959072 -
Cardiac Cath Lab Staff Radiation Exposure
|
||
Recruiting |
NCT05065073 -
Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
|
Phase 4 | |
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT05096442 -
Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions
|
N/A |